Zepbound pricing can vary by dose, refill timing, delivery format, and eligibility. LillyDirect lists a self-pay schedule for KwikPen and vial prescriptions, while some Medicare beneficiaries may have another coverage path.
As of August 19, 2026, LillyDirect lists the same advertised monthly self-pay prices for Zepbound KwikPen and single-dose vial prescriptions when the patient qualifies for and maintains the Zepbound Self Pay Journey Program. Lilly defines a month as 28 days.
The 2.5 mg dose is listed at $299 per 28-day month. It is the recommended starting dose for the first four weeks and is not intended as a maintenance dose. The 5 mg dose is listed at $399 per 28-day month and is a maintenance-strength option for eligible prescriptions.
The 7.5 mg, 10 mg, 12.5 mg, and 15 mg doses are each advertised at $449 per 28-day month through the Self Pay Journey Program. Eligibility requirements and refill timing apply, so the $449 amount should not be treated as an unconditional permanent retail price.
Lilly states that the $449 program price applies automatically on the first purchase of a qualifying 7.5 mg, 10 mg, 12.5 mg, or 15 mg single-dose vial or KwikPen beginning February 23, 2026. To retain the offer, the next refill purchase must be completed within 45 days of the delivery or receipt date of the previous prescription.
A refill completed more than 45 days later does not qualify for the purchase offer, and Lilly's regular price applies. The listed regular one-month prices are $499 for 7.5 mg and $699 for 10 mg, 12.5 mg, and 15 mg. That means a missed refill window could raise the listed monthly amount from $449 to $499 at 7.5 mg, or from $449 to $699 at the three higher strengths.
Lilly also states that the Self Pay Journey Program may be terminated, rescinded, revoked, or amended at any time, with or without notice. Eligibility and other restrictions apply. Reviewing the terms before each purchase can help clarify the amount expected at checkout.
The KwikPen is a multi-dose device containing four weekly doses for a 28-day month. A new pen needle is required for each injection, and pen needles are purchased separately. LillyDirect offers the KwikPen through self-pay with free home delivery or retail pickup at Walmart Pharmacy.
On March 16, 2026, Lilly announced that the KwikPen self-pay price was also made available at major pharmacies nationwide through a new KwikPen Self-Pay Savings Card. Retail pharmacy purchases may require presentation of the applicable savings card and compliance with its eligibility and program terms.
The single-dose vial contains one weekly dose. A monthly vial prescription includes four single-dose vials, and each injection requires a new needle and syringe. Lilly describes the vial as available exclusively through LillyDirect self-pay. Home delivery is available at no charge, and Walmart Pharmacy pickup may be available depending on the order. Needles and syringes are not included in the medicine price and can be added at checkout for an additional fee.
The choice between formats involves handling preferences, supply costs, and pickup or delivery availability. A prescription may be written for a particular format, so the prescribing healthcare professional and dispensing pharmacy can help clarify which option applies.
LillyDirect requires a valid prescription. A healthcare provider can send it electronically through an electronic health-record system, by phone at 1-855-723-4672, or by fax to LillyDirect Pharmacy. The pharmacy lists NPI 1912889320 and NCPDP 1574056, with an address at 1555 S Harding St, Ste 171-B68, Indianapolis, Indiana 46221.
Patients without an existing provider may be connected with an independent telehealth or in-person provider. The prescriber, not LillyDirect, determines whether Zepbound is medically appropriate.
After prescription verification, a LillyDirect dispensing pharmacy contacts the patient by text or email to confirm information, review available savings, select delivery or pickup, and prepare the order for checkout. LillyDirect says contact typically occurs within three to five business days after prescription verification. Most orders are processed and shipped within one to four days after checkout.
Temperature-sensitive medicine uses cold-chain packaging. LillyDirect home delivery is free, and the final price appears before checkout. Taxes, pharmacy charges, and injection supplies may add to the advertised medicine price.
Zepbound is FDA-approved for use with a reduced-calorie diet and increased physical activity to reduce excess body weight and maintain weight reduction long term in adults with obesity, or in adults with overweight who have at least one weight-related medical condition. It is also approved to treat moderate to severe obstructive sleep apnea in adults with obesity.
The FDA-approved starting schedule is 2.5 mg injected subcutaneously once weekly for four weeks. Dose escalation follows the direction of a healthcare professional and is intended to reduce the risk of gastrointestinal adverse reactions. The 2.5 mg strength is a treatment-starting dose rather than an approved maintenance dose.
Zepbound should not be used together with other tirzepatide-containing products or another GLP-1 receptor agonist unless specifically directed by a qualified clinician. The FDA label contains a boxed warning about thyroid C-cell tumors observed in rats. Zepbound is contraindicated for people with a personal or family history of medullary thyroid carcinoma or with Multiple Endocrine Neoplasia syndrome type 2.
Medication choice, dose changes, and safety questions require discussion with a qualified healthcare professional. Price information does not determine whether treatment is medically suitable.
Medicare beneficiaries should not automatically assume that the LillyDirect cash schedule is the only possible option. Beginning July 1, 2026, the Medicare GLP-1 Bridge program may cover the Zepbound KwikPen for eligible Medicare Part D beneficiaries at no more than $50 per 28-day month.
Eligibility depends on the program's clinical criteria, plan restrictions, prescription requirements, and prior-authorization process. The Bridge program covers the KwikPen for weight management, not the single-dose vial or single-dose pen. Separate pen needles are still required.
This Medicare coverage route is distinct from LillyDirect commercial self-pay pricing. Checking Part D plan information and the applicable authorization requirements before paying cash may help identify which pricing pathway applies.
Before placing an order, confirm the prescribed dose and format, since the monthly medicine amount ranges from $299 to $449 under the advertised Journey Program schedule. Confirm whether the prescription is for a KwikPen or four-vial monthly supply, then account for needles, syringes, taxes, and pharmacy charges where applicable.
For 7.5 mg through 15 mg, record the previous delivery or receipt date and review the 45-day refill requirement. A delayed refill can move the listed price to the regular amount. Program terms can also change, so the checkout total remains the most relevant amount for a specific order.
A valid prescription and clinical assessment are required. Comparing LillyDirect self-pay pricing with available Medicare coverage, retail pharmacy savings terms, or other eligible coverage routes can support a more informed medication decision.
LillyDirect lists Zepbound self-pay prices of $299 for 2.5 mg, $399 for 5 mg, and $449 for four higher strengths when the Self Pay Journey Program requirements are met. The 45-day refill window, added supply costs, format differences, and possible Medicare coverage can affect the final amount. Reviewing prescription details and checkout terms with a healthcare professional and dispensing pharmacy supports informed planning.
Sources: